updated 1/13/2011 12:46:02 PM ET 2011-01-13T17:46:02

CHARLESTON, S.C., Jan. 13, 2011 (GLOBE NEWSWIRE) -- Revolutions Medical Corporation ('Revolutions Medical" or the "Company") (OTCBB:RMCP) today announced that Ron Wheet, CEO & Chairman of Revolutions Medical Corporation, was interviewed today by Wall Street Reporter (WSR) Senior Analyst Juan Costello. The interview provides an overview of the Company, its technology and an update of Company achievements since the last WSR interview in September 2010.

Mr. Wheet also talked about the Company's management team, its transition from strictly R & D to sales, and expands on the recent significant Company news. The interview will be available to their global investor audience, which includes fund managers, stockbrokers, analysts, and investment bankers, as well as sophisticated individual investors.

The interview is available at www.wallstreetreporter.com , or directly via the link provided below:

http://www.wallstreetreporter.com/2011/01/revolutions-medical-otcbbrmcp-ceo-interview/

About Revolutions Medical Corporation

Revolutions Medical is a safety medical device and software application company. Its products include the RevVac Safety Syringe (FDA approved), safety blood drawing device; and the RevColorTM, RevDisplayTM and Rev3DTM software tools that are compatible with standard MRIs and standard Picture Archiving Computer Systems (PACS). The Company also has an exclusive license to a Breast Biopsy System (BBS) preliminary called RevTrack (FDA approved).

For additional information, please visit Revolutions Medical corporate website:  http://www.revolutionsmedical.com

To be added to the Revolutions Medical investor email list, please email Skey@revolutionsmedical.com with RMCP in the subject line.

Become a RevMed fan and follow the Company on Facebook -- visit http://www.Facebook.com/Revmed

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

CONTACT: Revolutions Medical Corporation
         Investor Relations:
         Scott Key
         (843) 518-0437
         Skey@revolutionsmedical.com

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 2.48%
$30K home equity loan FICO 5.80%
$75K home equity loan FICO 4.54%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.57%
13.57%
Cash Back Cards 17.91%
17.91%
Rewards Cards 17.15%
17.15%
Source: Bankrate.com